Zafgen (NASDAQ: ZFGN) has named Jeffrey Hatfield CEO of the Boston-based drug developer. Thomas Hughes, who has been Zafgen’s CEO since 2008, will continue as president and take on the newly created position of chief scientific officer. Both Hatfield and Hughes will serve on the company’s board of directors. Hatfield was most recently CEO of Vitae Pharmaceuticals. He has also worked in various roles at Bristol-Myers Squibb (NYSE: BMY). Zafgen’s lead drug candidate is in Phase 2 testing as a weight loss drug for diabetics.